Zepbound vs Mounjaro: Same Drug, Different Purposes

Zepbound is Eli Lilly's tirzepatide product approved for chronic weight management, per FDA prescribing information. Mechanistically, tirzepatide is a dual GIP/GLP-1 receptor agonist. That part is identical to Mounjaro because the active ingredient is the same. What changes is the approved indication and the clinical framing clinicians use when discussing treatment goals.

The trial result most often associated with Zepbound is SURMOUNT-1, published in NEJM in 2022. The reference file states the highest 15 mg dose produced average weight loss of 20.9% over 72 weeks versus 3.1% with placebo. SURMOUNT-2 reported 14.7% average weight loss in adults with type 2 diabetes, while SURMOUNT-3 reported 26.6% when tirzepatide followed intensive lifestyle intervention. Those are average trial outcomes, not individual guarantees.

Per FDA prescribing information, Zepbound dosing begins at 2.5 mg once weekly and escalates over time to maintenance doses of 10 mg or 15 mg. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and dyspepsia. The label also includes the thyroid C-cell tumor boxed warning observed in rodents and other important warnings that patients should review with a healthcare provider.

Mounjaro is the tirzepatide brand approved for type 2 diabetes, per FDA prescribing information. Because it contains the same active ingredient as Zepbound, many people assume the products are interchangeable in every sense. They are not. The active drug is the same, but the approved indication on the FDA label differs, and that can affect insurance rules, formulary decisions, and how treatment is documented.

The best-known direct comparison tied to Mounjaro is SURPASS-2, which the reference file describes as a study where tirzepatide showed superior A1C reduction and weight loss compared with semaglutide 1 mg in adults with type 2 diabetes. That is useful evidence for understanding tirzepatide's performance in diabetes care, but it serves a different question than the SURMOUNT obesity studies associated with Zepbound.

Mounjaro's dosing schedule follows the same weekly escalation structure as Zepbound, per FDA prescribing information. The side-effect profile is also materially similar because the active ingredient is the same. For patients, the biggest real-world difference is usually not the science of the molecule itself, but the indication, insurance coverage, and the clinical context in which a prescriber recommends it.

Both Zepbound and Mounjaro are typically about $1,000-1,100 per month without insurance as of early 2025.

Prices vary by pharmacy and location.

Coverage and prior-authorization rules may differ depending on whether the prescription is for a diabetes-labeled product or a weight-management-labeled product.

Patients should verify current pricing with their pharmacy and healthcare provider.

Pricing is approximate and based on the reference file as of early 2025. Prices vary by pharmacy and location. Consult your healthcare provider and pharmacy for current pricing.